<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206684</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-JYL-CC-01</org_study_id>
    <nct_id>NCT03206684</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer</brief_title>
  <official_title>A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, open, randomized, controlled clinical study to evaluate the efficacy and
      safety of PEG-rhG-CSF(PEGylated recombinant human granulocyte stimulating factor injection)
      in reducing neutropenia during TP(docetaxel+cisplatin) regiment simultaneous
      radiochemotherapy and adjuvant chemotherapy in patients with cervical cancer
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of III/IV neutropenia</measure>
    <time_frame>3 months</time_frame>
    <description>The incidence of III/IV neutropenia in each chemotherapy cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of FN</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of febrile neutropenia (FN) in each chemotherapy cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of chemotherapy dose adjustment</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of chemotherapy dose adjustment due to neutropenia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight &lt;45kg were given 3mg once per chemotherapy cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhG-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight&lt;45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight &lt;45kg were given 3mg once per chemotherapy cycle.</description>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <other_name>PEG-rhG-CSF single-dose administered</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF</intervention_name>
    <description>rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight&lt;45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.</description>
    <arm_group_label>rhG-CSF</arm_group_label>
    <other_name>rhG-CSF daily administered</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18, ≤70 years old;

          2. Cervical cancer patients diagnosed by histopathology;

          3. Need to receive multi-cycle radical concurrent radiochemotherapy;

          4. FN risk &gt; 20% if rhG-CSF was not accepted; High risk factors associated with FN and
             planed to use the same protocol in subsequent cycles(docetaxel+cisplatin regimen)；

          5. Performance status score(KPS)≥70;

          6. No obvious blood system disease,absolute neutrophil count（ANC）≥ 1.5×10^9/L, platelet
             count≥80×10^9 /L, hemoglobin（Hb）≥75 g/L, and no bleeding tendency;

          7. The patient signs the informed consent.

        Exclusion Criteria:

          1. With infection difficult to control, or received system antibiotic treatment within 72
             h before chemotherapy;

          2. Any bone marrow abnormalities and other hematopoietic ;

          3. Had received bone marrow or hematopoietic stem cell transplantation within 3 months;

          4. with other malignancies not cure, or with brain metastases;

          5. Liver function tests:total bilirubin(TBIL), alanine aminotransferase (ALT) and
             aspartate aminotransferase (AST) were all ≥2.5 times normal upper limit.

          6. Renal function tests: serum creatinine (Cr)&gt; 1.5 times normal upper limit;

          7. Allergic to the drugs or other genetic engineering biological products from
             Escherichia coli;

          8. Suffering from mental or neurological disorders;

          9. Investigator think it is not suitable for recruiting.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei Shi, MD</last_name>
    <phone>+86-29-84775425</phone>
    <email>Shimei82@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mei Shi, MD</last_name>
      <phone>+86-029-84775425</phone>
      <email>Shimei82@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Mei Shi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

